CJC-1295 with DAC

CJC-1295 with DAC research peptide primarily mimics endogenous GHRH by binding to GHRH receptors on anterior pituitary somatotroph cells, thereby activating adenylate cyclase and increasing cAMP levels to promote selective, sustained pulsatile growth hormone (GH) secretion. Additionally, this leads to elevated circulating IGF-1 production in the liver, enhanced protein synthesis, and improved metabolic homeostasis, while preserving physiological pulsatility and avoiding significant disruption of other pituitary hormones. Laboratory models, such as human pharmacokinetic assays and GHRH knockout rodent studies, reveal increases in GH levels by 2-10 fold for up to 6 days and IGF-1 by 0.5-3 fold for 9-11 days post-administration. These actions contribute to observed anabolic and regenerative effects, with recent research emphasizing its reassuring profile for balanced, long-term GH axis modulation in models of growth deficiency, aging, and metabolic inquiry.

• Growth hormone axis stimulation investigations

• Pulsatile GH and IGF-1 elevation mechanism analysis

• Sustained anabolic pathway and protein synthesis studies

• Body composition and lean mass regulation evaluations

• Metabolic homeostasis and endocrine feedback research

• Pharmacokinetic extension and albumin-binding examinations

• Teichman SL et al. J Clin Endocrinol Metab. 2006;91(3):799-805
• Alba M et al. J Clin Endocrinol Metab. 2008;93(6):2286-2292
• Ionescu M et al. J Clin Endocrinol Metab. 2006;91(4):1503-1508
• Jetté L et al. Drug Metab Dispos. 2005;33(9):1317-1325
• Van Hout MC et al. Hum Psychopharmacol. 2015;30(6):413-423